Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 209

1.

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.

Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG.

J Clin Oncol. 2019 Apr 23:JCO1802374. doi: 10.1200/JCO.18.02374. [Epub ahead of print]

PMID:
31013172
2.

An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy.

Liu PH, Shah RB, Li Y, Arora A, Ung PM, Raman R, Gorbatenko A, Kozono S, Zhou XZ, Brechin V, Barbaro JM, Thompson R, White RM, Aguirre-Ghiso JA, Heymach JV, Lu KP, Silva JM, Panageas KS, Schlessinger A, Maki RG, Skinner HD, de Stanchina E, Sidi S.

Nat Cell Biol. 2019 Feb;21(2):203-213. doi: 10.1038/s41556-018-0260-7. Epub 2019 Jan 21.

PMID:
30664786
3.

Sorafenib for Advanced and Refractory Desmoid Tumors.

Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK.

N Engl J Med. 2018 Dec 20;379(25):2417-2428. doi: 10.1056/NEJMoa1805052.

PMID:
30575484
4.

Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.

Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP.

JAMA Oncol. 2018 Dec 1;4(12):e184060. doi: 10.1001/jamaoncol.2018.4060. Epub 2018 Dec 13.

PMID:
30383140
5.

Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review.

Paoluzzi L, Maki RG.

JAMA Oncol. 2018 Oct 18. doi: 10.1001/jamaoncol.2018.4490. [Epub ahead of print]

PMID:
30347044
6.

A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.

D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Hensley ML, Hirst CM, Ezeoke MO, Ahn L, Qin LX, Antonescu CR, Lefkowitz RA, Maki RG, Schwartz GK, Tap WD.

Oncologist. 2018 Aug 20. pii: theoncologist.2018-0160. doi: 10.1634/theoncologist.2018-0160. [Epub ahead of print]

PMID:
30126857
7.

Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M.

Ann Oncol. 2018 Sep 1;29(9):1995-2002. doi: 10.1093/annonc/mdy253.

PMID:
30084934
8.

TERT promoter mutations in solitary fibrous tumour.

Demicco EG, Wani K, Ingram D, Wagner M, Maki RG, Rizzo A, Meeker A, Lazar AJ, Wang WL.

Histopathology. 2018 Nov;73(5):843-851. doi: 10.1111/his.13703. Epub 2018 Sep 19.

PMID:
29985536
9.

A Method to Summarize Toxicity in Cancer Randomized Clinical Trials.

Carbini M, Suárez-Fariñas M, Maki RG.

Clin Cancer Res. 2018 Oct 15;24(20):4968-4975. doi: 10.1158/1078-0432.CCR-17-3314. Epub 2018 May 8.

PMID:
29739789
10.

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H.

J Clin Oncol. 2018 Apr 1;36(10):1020-1044. doi: 10.1200/JCO.2017.77.0446. Epub 2018 Jan 30.

PMID:
29380678
11.

Sarcoma: The Merging of Science and Clinical Care.

Schwartz GK, Maki RG.

J Clin Oncol. 2018 Jan 10;36(2):99-100. doi: 10.1200/JCO.2017.76.9091. Epub 2017 Dec 8. No abstract available.

PMID:
29220300
12.

Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition.

Pang A, Carbini M, Moreira AL, Maki RG.

J Clin Oncol. 2018 Jan 10;36(2):210-216. doi: 10.1200/JCO.2017.74.9523. Epub 2017 Dec 8.

PMID:
29220296
13.

Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment.

Khan JA, Maki RG, Ravi V.

J Clin Oncol. 2018 Jan 10;36(2):194-201. doi: 10.1200/JCO.2017.74.9812. Epub 2017 Dec 8.

PMID:
29220293
14.

Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.

Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca; Cancer Genome Atlas Research Network.

Cell. 2017 Nov 2;171(4):950-965.e28. doi: 10.1016/j.cell.2017.10.014.

15.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S.

Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Lancet Oncol. 2018 Jan;19(1):e8.

PMID:
28988646
16.

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.

Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S.

J Clin Oncol. 2017 Oct 20;35(30):3433-3439. doi: 10.1200/JCO.2016.71.6605. Epub 2017 Aug 30.

PMID:
28854066
17.

Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.

Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A.

Oncologist. 2018 Jan;23(1):62-70. doi: 10.1634/theoncologist.2017-0161. Epub 2017 Jul 28.

18.

Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model.

Demicco EG, Wagner MJ, Maki RG, Gupta V, Iofin I, Lazar AJ, Wang WL.

Mod Pathol. 2017 Oct;30(10):1433-1442. doi: 10.1038/modpathol.2017.54. Epub 2017 Jul 21.

19.

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD.

Gynecol Oncol. 2017 Sep;146(3):531-537. doi: 10.1016/j.ygyno.2017.06.018. Epub 2017 Jun 24.

20.

Targeting sarcoma tumor-initiating cells through differentiation therapy.

Han D, Rodriguez-Bravo V, Charytonowicz E, Demicco E, Domingo-Domenech J, Maki RG, Cordon-Cardo C.

Stem Cell Res. 2017 May;21:117-123. doi: 10.1016/j.scr.2017.04.004. Epub 2017 Apr 13.

Supplemental Content

Loading ...
Support Center